Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe Inflammation's role in protein metabolism

NCT ID NCT06721910

Knowledge-focused Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether interleukin-6 (a protein involved in inflammation) changes how glucagon (a hormone) lowers amino acid levels in the blood. Twenty-six healthy volunteers received either a drug that blocks interleukin-6 or a placebo, then had their amino acid and hormone levels measured. The goal was to better understand how these signals control protein balance in the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tocilizumab
What this could lead to
If successful, this could help explain how inflammation affects protein metabolism, potentially guiding future treatments for conditions like diabetes or muscle wasting.
What could go wrong
This is a small, early-stage study in healthy people, not patients. Results may not apply to real diseases, and the intervention (tocilizumab) has known risks like infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

26 people

The number who actually took part.

Started

Jan 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Age 18 to 50 years * BMI 18.5 - 25 kg/m2 * Stable body weight in the past 6 months before study initiation * Women should be anovulatory on non-cyclic hormone replacement or hormonal contraception Exclusion criteria: * Previous medical history for any chronic condition in the last three months, active disease or abnormal physical examination as verified by a qualified physician * Body weight unstable in the past 6 months * Use of tobacco/nicotine * Alcohol consumption \>30g/day * Participation in an investigational drug trial within the past two months * Current intake of any drugs (prescribed, over the counter or recreational) * Known allergy to tocilizumab * Pregnant or lactating women, * Inability or unwillingness to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amino acid change are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amino acid change Glucagon resistance Healthy

Contacts and locations

Locations

  • University Hospital Basel

    Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.